N1 IL-4 Antagonist
Invented at Deakin University
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 157778 |
| Synonyms | N1 |
| Relevance |
There has been a marked increase in prevalence of atopic disease in regions such as Western Europe, the US, Australasia and Asia Pacific during recent years, especially in industrialised nations. In atopic individuals, an immune response is mounted by T cells that are activated by allergens, promoting T helper Type 2 (Th2) variant of cells. Once stimulated, these cells subsequently produce cytokines such as interleukin-4 (IL-4) and interleukin-13 (IL-13). In allergic cascades, cytokine IL-4/IL-13 binds to IL-4 receptor (IL-4R), consequently causing B and T cell proliferation and differentiation and the production of allergen-specific IgE antibodies by B cells. Although a range of techniques has been employed to down regulate the interaction between IL-4/IL-13 with IL-4Rα (e.g. monoclonal antibodies, antagonists and soluble receptors), the efficiency of these approaches still remains in doubt. Characterisation of novel antagonists that inhibit the combined effects of IL-4 and IL-13 is essential. Using Phage display, screening of a random 12-mer synthetic peptide library with human IL-4Rα was carried out in order to identify candidates. The peptide N1 was selected and synthesised for use in ELISA, demonstrating significant binding to IL-4Rα and inhibiting interaction with cytokine IL-4. The peptide was tested in a transfected HEK-Blue IL-4/IL13 cells, which produces alkaline phosphatase (AP) and showed a >50% inhibition with a simple colorimetric analysis. As this peptide targets the two most clinically important cytokines in allergy, it promises to provide for the future treatment for all IgE-mediated allergies. Publication - PMID: 26044177 |
| Antigen/Gene or Protein Targets | IL-4 |
| Research Area | Immunology |
